177 SVENSK KIRURGI • VOLYM 82 • NR 4 • 2024 Cancer 2017;17:810. 9. Bauden M, Kristl T, Andersson R, Marko-Varga G, Ansari D. Characterization of histone-related chemical modifications in formalin-fixed paraffin-embedded and fresh-frozen human pancreatic cancer xenografts using LC-MS/MS. Lab Invest 2017;97:279-288. 10. Zhou Q, Andersson R, Hu D, Bauden M, Sasor A, Bygott T, PawLowski K, Pla I, Marko-Varga G, Ansari D. Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis. Transl Res 2019;212:67-79. 11. Zhou Q, Bauden M, Andersson R, Hu D, Marko-Varga G, Xu J, Sasor A, Dai H, Pawłowski K, Said Hilmersson K, Chen X, Ansari D. YAP1 is an independent prognostic marker in pancreatic cancer and associated with extracellular matrix remodeling. J Transl Med 2020;18:77. 12. Lin L, Deng J, Yu J, Andersson R, Shen X, Ansari D, Xu X. Anoikisrelated genes linked with patient outcome in pancreatic cancer. Gene 2024; In Press. 13. Aronsson L, Andersson B, Andersson R, Tingstedt B, Bratlie SO, Ansari D. Intraductal papillary mucinous neoplasms of the pancreas: a nationwide registry-based study. Scand J Surg 2018;107:302-307. 14. Ansari D, Bauden M, Bergstrom S, Rylance R, Marko-Varga G, Andersson R. Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma. Br J Surg 2017;104:600-607. 15. Bengtsson A, Andersson R, Ansari D. Histological variants of pancreatic ductal adenocarcinoma: a survival analysis. Langenbecks Arch Surg 2024; In Press. 16. Ansari D, Althini C, Ohlsson H, Andersson R. Early-onset pancreatic cancer: a population-based study using the SEER registry. Langenbecks Arch Surg 2019;404:565-571. 17. Aronsson L, Andersson R, Ansari D. Artificial neural networks versus LASSO regression for the prediction of long-term survival after surgery for invasive IPMN of the pancreas. PLOS ONE 2021;16:e0249206: 18. Ansari D, Soreide K, Andersson B, Hansen CP, Seppanen H, Sparrelid E, Labori KJ, Kirkegard J, Kauhanen S, Mansson C, Nymo LS, Nortunen M, Bjornsson B, Kivivuori A, Tingstedt B, Bratlie SO, Waardal K, Laukkarinen J, Halimi A, Lindberg H, Olin H, Andersson R, Nordic Pancreatic Cancer N. Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contemporary practice. Scand J Gastroenterol 2024;1-8. 19. Zimmermannova O, Ferreira AG, Pereira CF. Orchestrating an immune response to cancer with cellular reprogramming. Genes Immun 2024;25:95-97. 20. Zimmermannova O, Ferreira AG, Ascic E, Velasco Santiago M, Kurochkin I, Hansen M, Met O, Caiado I, Shapiro IE, Michaux J, Humbert M, Soto-Cabrera D, Benonisson H, Silverio-Alves R, Gomez-Jimenez D, Bernardo C, Bauden M, Andersson R, Hoglund M, Miharada K, Nakamura Y, Hugues S, Greiff L, Lindstedt M, Rosa FF, Pires CF, Bassani-Sternberg M, Svane IM, Pereira CF. Restoring tumor immunogenicity with dendritic cell reprogramming. Sci Immunol 2023;8:eadd4817. 21. Andersson R, Pereira CF, Bauden M, Ansari D. Is immunotherapy the holy grail for pancreatic cancer? Immunotherapy 2019;11:1435-1438. Kirurgveckan Nya medlemmar i Svensk Kirurgisk Förening Vi hälsar följande nya medlemmar varmt välkomna: Caroline Beergrehn, St Görans sjukhus Mikaela Ihre Persson, Sundsvall kirurgklinik Donia Kaidi, Sahlgrenska Emma Skyman, Kirurgkliniken, NU-sjukvården Victor Strevens, Helsingborg Yao Xiao, Sahlgrenska Ida Matsson, St Görans sjukhus Christian Buchli, Karolinska universitetssjukhuset Therese Öqvist, Västmanlands sjukhus Oskar Swartling, Karolinska universitetssjukhuset
RkJQdWJsaXNoZXIy NjAyMDA=